Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 108
- 试验地点
- 2
- 主要终点
- Proportion of viable and exploitable immune organoids with engrafted tumor cells
研究概览
简要总结
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- — 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
- •Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
- •Brain tumors
- •Renal tumors
- •Neuroblastoma
- •Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
- •Affiliated to a social security system or beneficiary of the same.
排除标准
- •Any histology not mentioned in the inclusion criteria
- •Adult patient or parents/guardians incapable/incapable of giving its/their consent
- •Patients deprived of their liberty by a judicial or administrative decision
研究组 & 干预措施
Immune organoids from pediatric patient tissues using iPSC
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
干预措施: Skin biopsy (Procedure)
Immune organoids from pediatric patient tissues using iPSC
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
干预措施: Fresh tumor sample (Procedure)
Immune organoids from pediatric patient tissues using iPSC
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
干预措施: Blood sample (Biological)
Immune organoids from pediatric patient tissues using iPSC
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
干预措施: Healthy tissue from the tumor (Procedure)
Immune organoids from pediatric patient tissues using iPSC
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
干预措施: Spinal cerebrospinal fluid (SCF) (Procedure)
结局指标
主要结局
Proportion of viable and exploitable immune organoids with engrafted tumor cells
时间窗: until 5 years after enrolment
次要结局
未报告次要终点